EMA Authorised: NovoThirteen (catridecacog) — Novo Nordisk A/S

View source ↗

Summary

NovoThirteen (catridecacog) has been authorised by the EMA for inherited blood coagulation disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Blood Coagulation Disorders

Drugs mentioned

• NovoThirteen (recombinant factor XIII (rFXIII))

Snippet

Status: Authorised. Therapeutic area: Blood Coagulation Disorders, Inherited. MAH: Novo Nordisk A/S. Decision date: 27/08/2020